NASDAQ: LPTXLeap Therapeutics Inc Stock
$3.21+0.41 (+14.64%)
Updated Apr 22, 2024
LPTX Price
$3.21
Fair Value Price
$3.44
Market Cap
$82.18M
52 Week Low
$1.24
52 Week High
$10.20
P/E
-0.81x
P/B
1.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$81.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$44M
Beta
1.1
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
LPTX Overview
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LPTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LPTX ($3.21) is undervalued by 6.75% relative to our estimate of its Fair Value price of $3.44 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LPTX ($3.21) is not significantly undervalued (6.75%) relative to our estimate of its Fair Value price of $3.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LPTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LPTX due diligence checks available for Premium users.
Be the first to know about important LPTX news, forecast changes, insider trades & much more!
LPTX News
Valuation
LPTX fair value
Fair Value of LPTX stock based on Discounted Cash Flow (DCF)
Price
$3.21
Fair Value
$3.44
Undervalued by
6.75%
LPTX ($3.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LPTX ($3.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LPTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LPTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.81x
Industry
16.21x
Market
41x
LPTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.37x
Industry
5.82x
LPTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LPTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.5M
Profit Margin
0%
LPTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$72.8M
Liabilities
$12.7M
Debt to equity
0.21
LPTX's short-term assets ($71.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LPTX's short-term assets ($71.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LPTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LPTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.4M
Investing
$0.0
Financing
$0.0
LPTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LPTX vs Biotech Stocks
Leap Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.